Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135605 | 1.00 | KDM1A (0.63) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069642 | 1.00 | KDM1A (0.63) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL12870250 | 1.00 | KDM1A (0.63) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069714 | 0.85 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL25069626 | 0.82 | GRIA4 (0.51) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069675 | 0.82 | GRIA4 (0.51) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069500 | 0.82 | GRIA4 (0.51) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069502 | 0.82 | GRIA4 (0.51) | KDM1ASMN1; SMN2NPSR1MAOAMAOB | |
| SCHEMBL25069889 | 0.81 | KDM1A (0.69) | KDM1AMAOAMAOB | |
| SCHEMBL25069887 | 0.81 | KDM1A (0.69) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | KDM1A 3957/4885SMN1; SMN2 4359/4885NPSR1 252/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | KDM1A 3105/4885SMN1; SMN2 2387/4885NPSR1 50/4885 |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | KDM1A 2576/4885SMN1; SMN2 2782/4885NPSR1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.